257 results on '"Mok, T.S.K."'
Search Results
102. Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC): overall survival (OS) data from the phase IIb trial LUX-Lung 7 (LL7)
103. 356TiP Phase III clinical trials of atezolizumab in combination with chemotherapy in chemotherapy-naive patients with advanced NSCLC
104. LBA51 - Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study
105. 410O_PR - Alectinib (ALC) vs crizotinib (CRZ) in treatment-naïve ALK+ non-small-cell lung cancer (NSCLC): Asian vs non-Asian subgroup analysis of the ALEX study
106. 551P - Genomic profiling for advanced non-small-cell lung cancer (NSCLC) from circulating tumour DNA (ctDNA)
107. 420O - EAST-LC: Randomized controlled phase III trial of S-1 versus docetaxel (DOC) in patients with non-small cell lung cancer (NSCLC) who had received a platinum-based treatment: Results from patient-reported outcomes (PROs)
108. AURA3 Design: a Randomised, Phase III Study of Azd9291 Versus Second-Line Chemotherapy for Patients (PTS) with Egfr-Tki-Resistant (T790M) Advanced Non-Small Cell Lung Cancer
109. Overall Survival (OS) with Afatinib (A) Vs Chemotherapy (CT) in Patients (PTS) with Nsclc Harbouring EGFR Mutations (MUT): Subgroup Analyses by Race in Lux-Lung 3 (LL3) and Lux-Lung 6 (LL6)
110. EGFR Mutant Subset Analysis From Archer 1009: a Randomized Double Blind Phase 3 Efficacy and Safety Study of Dacomitinib Versus Erlotinib for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
111. 1298O_PR - Alectinib vs crizotinib in treatment-naïve ALK+ NSCLC: CNS efficacy results from the ALEX study
112. LBA50 - Overall survival (OS) for first-line crizotinib versus chemotherapy in ALK+ lung cancer: Updated results from PROFILE 1014
113. 1383TiP - Blood first line ready screening trial (B-F1RST) and blood first assay screening trial (BFAST) enable clinical development of novel blood-based biomarker assays for tumor mutational burden (TMB) and somatic mutations in 1L advanced or metastatic NSCLC
114. 1295O - Blood-based biomarkers for cancer immunotherapy: Tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in 2L+ NSCLC (POPLAR and OAK)
115. 146TiP - EXalt3: A phase III study of ensartinib (X-396) in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)
116. 58TiP - IMpower133: Phase I/III trial of first-line atezolizumab with carboplatin and etoposide in ES-SCLC
117. A Phase Ii Study on Combination of Axitinib and Transarterial Chemoembolization (Tace) for Treatment of Inoperable Hepatocellular Carcinoma (Hcc)
118. Overall and Intracranial (Ic) Efficacy Results and Time to Symptom Deterioration in Profile 1014: 1St-Line Crizotinib Vs Pemetrexed - Platinum Chemotherapy (Ppc) in Patients (Pts) with Advanced Alk-Positive Non-Squamous Non-Small Cell Lung Cancer (Nsclc)
119. Randomised, Multicentre, Phase Iii, Open-Label Study of Alectinib Vs Crizotinib in Treatment-Naïve Anaplastic Lymphoma Kinase (Alk)-Positive Advanced Nsclc (Alex Study)
120. Gefitinib/Chemotherapy Vs Chemotherapy in Epidermal Growth Factor Receptor (Egfr) Mutation-Positive Non-Small-Cell Lung Cancer (Nsclc) After Progression on First-Line Gefitinib: the Phase Iii, Randomised Impress Study
121. Two Phase III Studies Evaluating Ceritinib in Patients (Pts) with Anaplastic Lymphoma Kinase (Alk)-Rearranged (Alk+) Non-Small Cell Lung Cancer (Nsclc): Ascend-4 and Ascend-5
122. Aspiration: First-Line Erlotinib (E) Until and Beyond Recist Progression (Pd) in Asian Patients (Pts) with Egfr Mutation-Positive (Mut+) Nsclc
123. Efficacy Analysis of Gefitinib +/- Ficlatuzumab in Serum Proteomic Based Subgroups of Patients with Previously Untreated Lung Adenocarcinoma
124. Phase 3 Randomized Study (ARCHER 1050) of 1st-Line Dacomitinib vs Gefitinib for Advanced NSCLC with EGFR Mutation(S)
125. LBA42_PR - Ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with CT and crizotinib (CRZ): Results from the confirmatory phase 3 ASCEND-5 study
126. LBA43 - Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC): overall survival (OS) data from the phase IIb trial LUX-Lung 7 (LL7)
127. 1431TiP - A Phase III study of atezolizumab with carboplatin plus etoposide in patients with extensive-stage small cell lung cancer (IMpower133)
128. 1294TiP - Phase III clinical trials in chemotherapy-naive patients with advanced NSCLC assessing the combination of atezolizumab and chemotherapy
129. 1246P - Adjusted indirect comparison using propensity score matching of osimertinib to doublet chemotherapy in patients with EGFRm T790M NSCLC who have progressed after EGFR-TKI
130. 1236P - Global named patient use (NPU) program of afatinib, an oral ErbB family blocker, in heavily pretreated advanced non-small cell lung carcinoma (NSCLC) patients who progressed following prior therapies, including erlotinib or gefitinib (E/G)
131. 1230P - Time-to-treatment failure (TTF) with first-line afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) advanced non-small-cell lung cancer (NSCLC): Randomized phase IIb LUX-lung 7 (LL7) trial
132. 1218PD - EAST-LC: Randomized controlled phase III trial of S-1 versus docetaxel in patients with non-small-cell lung cancer who had received a platinum-based treatment
133. 1208O - Phase 2 study of ceritinib in ALKi-naïve patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC): Whole body responses in the overall pt group and in pts with baseline brain metastases (BM)
134. 1201O - Gefitinib/chemotherapy vs chemotherapy in EGFR mutation-positive NSCLC after progression on 1st line gefitinib (IMPRESS study): Final overall survival (OS) analysis
135. 92P ARCHER 1050: PHASE III RANDOMIZED STUDY OF 1ST-LINE DACOMITINIB (D) VS GEFITINIB (G) FOR ADVANCED (ADV) NON-SMALL CELL LUNG CANCER (NSCLC) IN PATIENTS (PTS) WITH ACTIVATING EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION(S)
136. Phase II Study of Two Eribulin Regimens in Combination with Erlotinib in Patients (PTS) with Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)
137. Phase III Study of Crizotinib Versus Pemetrexed or Docetaxel Chemotherapy in Patients with Advanced Alk-Positive Non-Small Cell Lung Cancer (NSCLC) (Profile 1007)
138. Pooled Analysis of Clinical Outcomes for Patients with EGFR Mutations in Non-Small-Cell Lung Cancer: An Update
139. Clinical Genotyping and Efficacy Outcomes: Exploratory Biomarker Data from the Phase II Abigail Study of 1st-Line Bevacizumab + Chemotherapy in Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC)
140. Tumour Biomarker and Plasma Time Course Data from Abigail, A Phase II Study of 1st-Line Bevacizumab + Chemotherapy in Advanced Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC)
141. New Strategies on the Horizon
142. Biomarker Analyses and Overall Survival (OS) from the Randomized, Placebo-Controlled, Phase 3, Fastact-2 Study of Intercalated Erlotinib with First-Line Chemotherapy in Advanced Non-Small-Cell Lung Cancer (NSCLC)
143. Activity of Afatinib in Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations in Lux-Lung 3, A Phase III Trial of Afatinib or Cisplatin/Pemetrexed in EGFR Mutation-Positive Lung Cancer
144. Lux-Lung 3: Symptom and Health-Related Quality of Life Results from a Randomized Phase III Study in 1st-Line Advanced NSCLC Patients Harbouring EGFR Mutations
145. A Randomized Phase (PH) 2 Study with Exploratory Biomarker Analysis of Ficlatuzumab (F) A Humanized Hepatocyte Growth Factor (HGF) Inhibitory MAB in Combination with Gefitinib (G) Versus G in Asian Patients (PTS) with Lung Adenocarcinoma (LA)
146. Dacomitinib (PF-00299804), An Irreversible Pan-Her Tyrosine Kinase Inhibitor (TKI), For First-Line Treatment of EGFR-Mutant or Her2-Mutant or -Amplified Lung Cancers
147. Monotherapy Administration of Sorafenib in Patients with Non-Small Cell Lung Cancer: Phase III, Randomized, Double-Blind, Placebo-Controlled Mission Trial
148. Association Between Tumor Egfr and Kras Mutation Status and Clinical Outcomes in Nsclc Patients Randomized to Sorafenib Plus Best Supportive Care (BSC) or Bsc Alone: Subanalysis of the Phase III Mission Trial
149. 9132 POSTER Efficacy Outcomes in First-line Treatment of Advanced NSCLC With Gefitinib (G) vs Carboplatin/paclitaxel (C/P) by Epidermal Growth Factor Receptor (EGFR) Gene-copy Number Score and by Most Common EGFR Mutation Subtypes – Exploratory Data From IPASS
150. 9134 POSTER Tumour Response, Skin Rash and Health-related Quality of Life (HRQoL) – Post-hoc Data From the IPASS Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.